Drug Trial Radar · NCT05650580
TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
26
Planned (sponsor's estimate)
Start
Apr 23, 2023
Primary completion
Jul 30, 2025
Study completion Dec 30, 2025
Sponsor
- Lead sponsor
- Tarapeutics Science Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 1 dose escalation and expanded cohort study of TR115 in the treatment of adult patients with relapsed/refractory non-hodgkin's lymphoma or advanced solid tumors.
Conditions
- Non-Hodgkin's Lymphoma, Relapsed
- Non-Hodgkin's Lymphoma Refractory
- Advanced Solid Tumor
Interventions
TR115Drug
TR115 is supplied as tablet with dosage strength of 100mg. TR115 tablet will be administered orally on a continuous twice daily (BID) schedule and a treatment cycle is defined as 28 days for the purposes of scheduling procedures and evaluations. TR115 tablets will be given until there appears evidence of progressive disease , intolerable toxicity, or the subject discontinues from the study treatment for other reasons. Proposed daily dose (BID): 100mg, 200mg, 400mg, 800mg, 1200mg, 1600mg. It is possible for additional and/or intermediate dose levels to be added during the course of the study. Cohorts may be added at any dose level below the Maximum Tolerated Dose (MTD) in order to better understand safety, Pharmacokinetic (PK) or Pharmacodynamic (PD).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events and serious adverse eventsTime frame: from the first dose to within 30 days after the last dose
- dose limited toxicitiesTime frame: within 31 days after the first dose
- maximum tolerated doseTime frame: Throughout the study for approximately 2 years
- recommedded phase 2 doseTime frame: Throughout the study for approximately 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The first affiliated hospital, Zhejiang university school of medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.